LBOVI-B-4Recombinant human growth hormone (rhGH) has no effect on activities of hepatic cytochrome P4501A2 (CYP1A2), N-acetyltransferase 2 (NAT2), xanthine oxidase (XO) or cytochrome P4502D6 in children with idiopathic growth hormone (GH) deficiency

2006 ◽  
Vol 79 (2) ◽  
pp. P84-P84 ◽  
Author(s):  
M KENNEDY ◽  
D DAVIS ◽  
N SMITH ◽  
W PIERCE ◽  
T LIN ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Xanthine Oxidase ◽  
Human Growth Hormone ◽  
Gh Deficiency ◽  
Human Growth ◽  
Cytochrome P4501a2 ◽  
Hepatic Cytochrome

scholarly journals The Use and Abuse of Human Growth Hormone in Sports

2018 ◽  
Vol 10 (5) ◽  
pp. 419-426 ◽  
Author(s):  
David M. Siebert ◽  
Ashwin L. Rao
Keyword(s):  
Growth Hormone ◽  
Human Growth Hormone ◽  
Sports Medicine ◽  
Gh Deficiency ◽  
Adult Population ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Level Of Evidence ◽  
Therapeutic Benefits ◽  
Rhgh Treatment

Context: Recombinant human growth hormone (rHGH) has become a target of abuse in the sporting world. Conversely, sports medicine clinicians may encounter athletes using rHGH to achieve normalcy in the context of growth hormone (GH) deficiency. Evidence Acquisition: Medline and PubMed databases were queried using the following keywords: GH, GH physiology, GH deficiency, acromegaly, GH athlete, GH sports, GH athletic performance, and GH deficiency concussion. Articles focusing on GH physiology, deficiency, excess, and its effects in both deficient and healthy patients were included. Study Design: Clinical review. Level of Evidence: Level 3. Results: GH is a naturally occurring hormone with important roles in human physiology. Patients with GH deficiency (GHD) present variably, and GHD has numerous etiologies. rHGH treatment has substantial therapeutic benefits for patients with GHD. The benefits of rHGH treatment in otherwise-healthy adults are uncertain. GH excess may cause health problems such as acromegaly. Professional, collegiate, and international sports leagues and associations have banned rHGH use to maintain athlete health, safety, and fair play. Athletes misusing GH may face prolonged suspensions from competition. Implementing GH abuse testing is challenging, but new methods, such as the biomarker testing procedure, are being finalized. Conclusion: rHGH is not only an important therapeutic agent for GH-deficient patients but also a target of abuse in competitive athletics. Its benefits in a healthy, adult population are uncertain. A safe exercise and competition plan, developed with a physician knowledgeable of GH use, physiology, and abuse potential, should be of benefit to a longitudinal clinician-patient relationship.

Sign in / Sign up

Export Citation Format

Share Document